数位基因组设备市场：现况分析与预测（2023-2030）

由于慢性病盛行率不断上升，数位基因组设备市场预计在预测期内将以 14% 的复合年增长率强劲增长。 例如，根据世界卫生组织 (WHO) 的数据，癌症是全球主要死亡原因之一，2020 年约有 1,000 万人死于癌症，约占死亡人数的六分之一。

依产品类型，市场分为序列及分析仪器、DNA/RNA 分析试剂盒、序列及分析软体、样品製备仪器等。 根据我们的分析，定序和分析设备领域将在 2022 年占据主导份额。 定序和分析设备领域是数位基因组设备市场的重要组成部分。 此细分市场包括用于分析遗传数据并识别 DNA 序列模式和突变的各种仪器，例如下一代定序仪 (NGS) 和桑格定序仪。 由于该领域存在各种仪器，因此序列和分析仪领域占据了压倒性的市场份额。

依应用划分，市场分为微生物学、生殖/遗传学、移植/农业和法医学。 在预测期内，微生物学领域预计在数位基因组设备市场中将以更高的复合年增长率成长。 人类微生物组是生活在人体内的复杂微生物群落。 随着科学家试图了解微生物在人类健康和疾病中的作用，对微生物组的研究正在增加。 因此，对能够分析微生物基因组的数位基因组仪器的需求不断增长。

市场根据最终用户细分为学术研究机构、诊断和法医实验室、医院和生物製药公司。 根据我们的分析，到2022年，医院板块将占据主导份额。 先进技术的采用增加、对基因技术的需求不断增加以及对更高效、更具成本效益的医疗保健的需求推动了医院领域的成长。

为了更了解该产业的市场采用情况，市场分为北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、义大利、西班牙、欧洲其他地区）、亚洲太平洋地区（根据世界其他地区（中国、日本、印度、韩国、澳洲和其他亚太地区）的全球影响力进行分析。 北美是医疗设备行业许多主要参与者的所在地，该地区高水准的医疗保健支出正在促进该地区数位基因组设备市场的成长。 此外，能够快速识别疾病和感染的快速诊断测试在北美变得越来越流行。 数位基因组设备可用于开发此类测试，这推动了对这些设备的需求。

目录

第 1 章市场介绍

• 市场定义
• 主要目标
• 利害关係人
• 限制

第 2 章研究方法或假设

• 调查过程
• 调查方法
• 受访者简介

第 3 章市场总结

第 4 章执行摘要

第 5 章新型冠状病毒感染（COVID-19）对全球数位基因组设备市场的影响

第 6 章 2020-2030 年全球数位基因组设备市场收入

第 7 章按产品类型划分的市场洞察

• 定序与分析设备
• DNA/RNA 分析试剂盒
• 定序与分析软体
• 样品製备设备
• 其他

第 8 章按应用划分的市场洞察

• 微生物学
• 繁殖和遗传学
• 移植和农业
• 法医学

第 9 章最终使用者的市场洞察

• 学术研究所
• 诊断与法医实验室
• 医院
• 生物製药公司

第 10 章按地区划分的市场洞察

• 北美数位基因组设备市场
  • 美国
  • 加拿大
  • 其他北美地区
• 欧洲数位基因组设备市场
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他欧洲地区
• 亚太地区数位基因组设备市场
  • 中国
  • 日本
  • 印度
  • 韩国
  • 亚太地区的其他国家/地区
• 其他地区的数位基因组设备市场

第 11 章数位基因组设备市场动态

• 市场促进因素
• 市场挑战
• 影响分析

第 12 章数位基因组设备市场机会

第 13 章数位基因组设备市场趋势

第 14 章需求面与供给面分析

• 需求方分析
• 供给面分析

第 15 章价值链分析

第 16 章价格分析

第 17 章策略洞察

第 18 章竞争场景

• 竞争状况
  • 波特五力分析

第 19 章公司简介

• QIAGEN
• Thermo Fisher Scientific Inc.
• BD
• Agilent Technologies, Inc
• Illumina, Inc.
• PacBio
• BIOMERIEUX
• Genomic Health, Inc.
• PerkinElmer Inc
• Quest Diagnostics

第 20 章免责声明

The Digital Genome Instrument (DGI) is a groundbreaking technology that allows for the rapid and accurate analysis of DNA samples. It is a portable device that can be used in remote locations or in the field, making it an ideal tool for researchers, doctors, and other professionals who need to quickly and efficiently collect and analyze DNA samples. The increasing prevalence of genetic disorders, along with the surging demand for personalized medicine is the major factor responsible for the growth of the digital genome instrument market. For instance, as per Medline Plus, about 1 in 200,000 people in the United States are diagnosed with syndrome A each year.

Digital Genome Instrument Market is expected to grow at a strong CAGR of 14% during the forecast period owing to the increasing prevalence of chronic diseases. For instance, as per the World Health Organization, cancer is one of the leading causes of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths.

Based on product type, the market is segmented into sequencing & analyzer instruments, DNA/RNA analysis kits, sequencing & analysis software, sample preparation instruments, and others. As per our analysis, the sequencing & analyzer instruments segment held a dominant share in 2022. The sequencing & analyzer instruments segment is a critical part of the digital genome instrument market. This segment includes a range of instruments such as next-generation sequencing (NGS) and Sanger sequencing instruments that are used to analyze genetic data and identify patterns and variations in DNA sequences. Due to the presence of a wide range of instruments in the segment, the sequencing & analyzer segment is witnessing dominating share of the market.

Based on the application, the market is segmented into microbiology, reproductive & genetic, transplantation & agriculture, and forensics. The microbiology segment is expected to grow with a higher CAGR in the digital genome instrument market during the forecast period. The human microbiome is a complex community of microorganisms that live on and inside the human body. Research into the microbiome is increasing, as scientists seek to understand the role of these microorganisms in human health and disease. This is driving the demand for digital genome instruments that can analyze microbial genomes.

Based on end-users, the market is segmented into academic research institutes, diagnostics & forensics labs, hospitals, and biopharmaceutical companies. As per our analysis, the hospital's segment held a dominant share in 2022. The growth of the hospital segment is being driven by the increasing adoption of advanced technology, the growing demand for genetic technology, and the need for more efficient and cost-effective healthcare.

For a better understanding of the market adoption of the industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Rest of World. North America is home to a large number of leading players in the medical device industry, and the region has a high level of healthcare spending, which has contributed to the growth of the digital genome instrument Market in the region. Additionally, Rapid diagnostic tests are becoming increasingly popular in North America, as they allow for the rapid identification of diseases and infections. Digital genome instruments can be used to develop these tests, which is driving the demand for these instruments.

Some of the major players operating in the market include: QIAGEN; Thermo Fisher Scientific Inc.; BD; Agilent Technologies, Inc; Illumina, Inc.; PacBio; BIOMERIEUX; Genomic Health, Inc.; PerkinElmer Inc; and Quest Diagnostics.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Digital Genome Instrument Market
• 2.2. Research Methodology of the Digital Genome Instrument Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL DIGITAL GENOME INSTRUMENT MARKET COVID-19 IMPACT

6 GLOBAL DIGITAL GENOME INSTRUMENT MARKET REVENUE, 2020-2030F

7 MARKET INSIGHTS BY PRODUCT TYPE

• 7.1. Sequencing & Analyzer Instruments
• 7.2. DNA/RNA analysis kits
• 7.3. Sequencing & analysis software
• 7.4. Sample preparation instruments
• 7.5. Others

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Microbiology
• 8.2. Reproductive & Genetic
• 8.3. Transplantation & Agriculture
• 8.4. Forensics

9 MARKET INSIGHTS BY END-USERS

• 9.1. Academic research institutes
• 9.2. Diagnostics & forensics labs
• 9.3. Hospitals
• 9.4. Biopharmaceutical companies

10 MARKET INSIGHTS BY REGION

• 10.1. North America Digital Genome Instrument Market
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe Digital Genome Instrument Market
  • 10.2.1. Germany
  • 10.2.2. UK
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific Digital Genome Instrument Market
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. South Korea
  • 10.3.5. Rest of APAC
• 10.4. Rest of the World Digital Genome Instrument Market

11 DIGITAL GENOME INSTRUMENT MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 DIGITAL GENOME INSTRUMENT MARKET OPPORTUNITIES

13 DIGITAL GENOME INSTRUMENT MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 PRICING ANALYSIS

17 STRATEGIC INSIGHTS

18 COMPETITIVE SCENARIO

• 18.1. Competitive Landscape
  • 18.1.1. Porters Fiver Forces Analysis

19 COMPANY PROFILED

• 19.1. QIAGEN
• 19.2. Thermo Fisher Scientific Inc.
• 19.3. BD
• 19.4. Agilent Technologies, Inc
• 19.5. Illumina, Inc.
• 19.6. PacBio
• 19.7. BIOMERIEUX
• 19.8. Genomic Health, Inc.
• 19.9. PerkinElmer Inc
• 19.10. Quest Diagnostics

20 DISCLAIMER